Literature DB >> 8698508

Tumor necrosis factor alpha and interleukin-12 contribute to resistance to the intracellular bacterium Brucella abortus by different mechanisms.

Y Zhan1, Z Liu, C Cheers.   

Abstract

Both interleukin-12 (IL-12) and tumor necrosis factor alpha (TNF-alpha) are produced early in intracellular bacterial infection. Depletion of either IL-12 or TNF-alpha by a single injection of specific antibody 4 h before the injection of Brucella abortus 19 led to the exacerbation of infection 2 weeks later. Whereas the effect of IL-12 depletion on resistance was persistent and exacerbation was still significant 6 weeks later, the bacterial numbers in mice depleted of TNF-alpha were similar to the bacterial numbers in control infected mice by 6 weeks postinfection. Massive splenomegaly, which is often seen in 2-week Brucella-infected mice, was not observed in IL-12- or TNF-alpha-depleted mice. Both IL-12- and TNF-alpha-depleted mice showed reduced cell accumulation in the spleen compared with the massive cell accumulation in control infected mice. Granuloma formation in livers was much reduced in IL-12-depleted mice but not in TNF-alpha-depleted mice. Gamma interferon (IFN-gamma) production by cells from TNF-alpha-depleted mice was not significantly different from that of cells from control infected mice. In contrast, the production of IFN-gamma by both CD4+ and CD8+ T cells from IL-12-depleted mice was greatly reduced, compared with that from control infected mice. This effect was still observed when the antibody injection was delayed for up to 7 days postinfection, but injections of anti-IL-12 antibody into mice with established Brucella infection had no significant effect on IFN-gamma production by T cells. Taken together, these results suggested that IL-12 contributed to resistance mainly via an IFN-gamma-dependent pathway and had a profound effect on the induction of acquired cellular resistance. In contrast, TNF-alpha was involved in resistance possibly via direct action on effector cells and may not be essential for the induction of acquired cellular resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698508      PMCID: PMC174139          DOI: 10.1128/iai.64.7.2782-2786.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  IFN-gamma-producing ability as a possible marker for the protective T cells against Mycobacterium bovis BCG in mice.

Authors:  I Kawamura; H Tsukada; H Yoshikawa; M Fujita; K Nomoto; M Mitsuyama
Journal:  J Immunol       Date:  1992-05-01       Impact factor: 5.422

Review 2.  Natural immunity: a T-cell-independent pathway of macrophage activation, defined in the scid mouse.

Authors:  G J Bancroft; R D Schreiber; E R Unanue
Journal:  Immunol Rev       Date:  1991-12       Impact factor: 12.988

3.  Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids.

Authors:  L C Green; D A Wagner; J Glogowski; P L Skipper; J S Wishnok; S R Tannenbaum
Journal:  Anal Biochem       Date:  1982-10       Impact factor: 3.365

4.  Pathogen-induced Th1 phenotype development in CD4+ alpha beta-TCR transgenic T cells is macrophage dependent.

Authors:  C S Hsieh; S E Macatonia; A O'Garra; K M Murphy
Journal:  Int Immunol       Date:  1993-04       Impact factor: 4.823

5.  Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist.

Authors:  C S Tripp; S F Wolf; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

6.  Endogenous tumor necrosis factor alpha is required for enhanced antimicrobial activity against Toxoplasma gondii and Listeria monocytogenes in recombinant gamma interferon-treated mice.

Authors:  J A Langermans; M E van der Hulst; P H Nibbering; R van Furth
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

7.  Endogenous tumor necrosis factor, interleukin-6, and gamma interferon levels during Listeria monocytogenes infection in mice.

Authors:  A Nakane; A Numata; T Minagawa
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

8.  Inhibition of B lymphocyte activation by interferon-gamma.

Authors:  D S Reynolds; W H Boom; A K Abbas
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

9.  Cytokine response of T-cell subsets from Brucella abortus-infected mice to soluble Brucella proteins.

Authors:  Y Zhan; J Yang; C Cheers
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

10.  Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response.

Authors:  J P Sypek; C L Chung; S E Mayor; J M Subramanyam; S J Goldman; D S Sieburth; S F Wolf; R G Schaub
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  47 in total

1.  Effect of exogenous interleukin-18 (IL-18) and IL-12 in the course of Brucella abortus 2308 infection in mice.

Authors:  Paolo Pasquali; Rosanna Adone; Louis C Gasbarre; Claudia Pistoia; Franco Ciuchini
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

2.  Major outer membrane protein Omp25 of Brucella suis is involved in inhibition of tumor necrosis factor alpha production during infection of human macrophages.

Authors:  V Jubier-Maurin; R A Boigegrain; A Cloeckaert; A Gross; M T Alvarez-Martinez; A Terraza; J Liautard; S Köhler; B Rouot; J Dornand; J P Liautard
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Either B7-1 or B7-2 is required for Listeria monocytogenes-specific production of gamma interferon and interleukin-2.

Authors:  Y Zhan; C Cheers
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

4.  IL-12Rβ2 is critical for survival of primary Francisella tularensis LVS infection.

Authors:  Amanda A Melillo; Oded Foreman; Karen L Elkins
Journal:  J Leukoc Biol       Date:  2013-02-25       Impact factor: 4.962

5.  Recombinant Lactococcus Lactis Displaying Omp31 Antigen of Brucella melitensis Can Induce an Immunogenic Response in BALB/c Mice.

Authors:  Hoda Shirdast; Fatemeh Ebrahimzadeh; Amir Hossein Taromchi; Yousef Mortazavi; Abdolreza Esmaeilzadeh; Mohammad Hadi Sekhavati; Keivan Nedaei; Esmat Mirabzadeh
Journal:  Probiotics Antimicrob Proteins       Date:  2021-02       Impact factor: 4.609

6.  The adjuvant effect of a single dose of interleukin-12 on murine immune responses to live or killed Brucella abortus strain RB51.

Authors:  I K Lee; S C Olsen; M Kehrli; C A Bolin
Journal:  Can J Vet Res       Date:  1999-10       Impact factor: 1.310

7.  Protective efficacy of a Brucella vaccine using a Salmonella-based delivery system expressing Brucella Omp3b, BCSP31, and SOD proteins against brucellosis in Korean black goats.

Authors:  Won-Kyong Kim; Ja-Young Moon; Jeong-Sang Cho; Jin Hur
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

8.  Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; A Mejias; C Somers; S Chavez-Bueno; G H McCracken; R D Hardy
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

9.  Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godefroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

10.  TLR9 is required for MAPK/NF-κB activation but does not cooperate with TLR2 or TLR6 to induce host resistance to Brucella abortus.

Authors:  Marco Túlio Gomes; Priscila Carneiro Campos; Guilherme de Sousa Pereira; Daniella Castanheira Bartholomeu; Gary Splitter; Sergio Costa Oliveira
Journal:  J Leukoc Biol       Date:  2015-11-17       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.